Clinical Trial Update: Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection [Phase 3]

View source ↗

Summary

This is a Phase 3 trial update on lenacapavir plus emtricitabine/tenofovir alafenamide for pre-exposure prophylaxis in adolescent girls and young women at risk …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Descovy (emtricitabine/tenofovir alafenamide) (emtricitabine/tenofovir alafenamide)
• Sunlenca (lenacapavir) (lenacapavir)

Snippet

Sponsor: Gilead Sciences | Conditions: Pre-Exposure Prophylaxis of HIV Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-19